Analysts expect Allogene Therapeutics, Inc. to report revenue of 2,353.26 for Q3 26, against a range of 2,227.59 to 2,478.93. The most recent reported quarter, Q2 26, came in at 4.64 M , in line with the 2,431.99 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.64 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 11,321.03 | 9,902.97 | 2,647.74 | 0.00 | 2,552.02 | 2,507.41 | 2,293.56 | 2,518.38 | 2,478.93 | 2,526.99 | 5,478.42 | 5,551.88 | 13,824.72 | 965,165.14 | 18.51 M | 22.93 M | ||||||||||
| Low Estimate | 9,561.25 | 9,099.45 | 2,233.34 | 0.00 | 2,143.66 | 2,352.07 | 1,888.18 | 2,345.60 | 2,227.59 | 2,319.99 | 5,054.28 | 4,708.22 | 11,766.14 | 810,003.02 | 16.10 M | 18.90 M | ||||||||||
| Consensus Estimate | 10,441.14 | 9,501.21 | 2,440.54 | 0.00 | 2,347.84 | 2,429.74 | 2,090.87 | 2,431.99 | 2,353.26 | 2,423.49 | 5,266.35 | 5,130.05 | 12,795.43 | 887,584.08 | 17.30 M | 20.92 M |
Analysts expect Allogene Therapeutics, Inc. to report earnings per share of -0.14 for Q3 26, against a range of -0.15 to -0.13. The most recent reported quarter, Q2 26, came in at -0.13, a 27.8% beat against the -0.18 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.32 | -0.28 | -0.28 | -0.23 | -0.19 | -0.17 | -0.18 | -0.13 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.33 | -0.29 | -0.29 | -0.26 | -0.21 | -0.23 | -0.18 | -0.17 | -0.13 | -0.15 | -0.14 | -0.15 | -0.14 | -0.11 | -0.15 | -0.13 | ||||||||||
| Low Estimate | -0.37 | -0.35 | -0.31 | -0.30 | -0.25 | -0.25 | -0.22 | -0.19 | -0.15 | -0.17 | -0.18 | -0.17 | -0.16 | -0.13 | -0.17 | -0.15 | ||||||||||
| Consensus Estimate | -0.35 | -0.32 | -0.30 | -0.28 | -0.23 | -0.24 | -0.20 | -0.18 | -0.14 | -0.16 | -0.16 | -0.16 | -0.15 | -0.12 | -0.16 | -0.14 |
Pull Wall Street consensus for Allogene Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ALLO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ALLO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=ALLO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();